Approaches in the Treatment of Uncontrolled Hypertension

AUTHOR(S) / AUTOR(I): Vladimir Miloradović , Neda Ćićarić

Download Full Pdf   

DOI: 10.46793/KARNEF25.332M

ABSTRACT / SAŽETAK:

Despite the availability of antihypertensive drugs, many patients worldwide have uncontrolled hypertension (1,2). In this regard, the term „resistant hypertension“ was introduced, with a prevalence of 10%-20% in hypertensive patients (3). According to the current guidelines of the European Association of Cardiology, hypertension is defined as resistant when the treatment strategy, which includes appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of diuretics (thiazides and thiazide-like diuretics), blockers of the renin-angiotension-aldosterone system (RAAS) and calcium channel blockers, fails to lower systolic arterial pressure <140 mm Hg and/or diastolic arterial pressure <90 mm Hg (4). Compared to patients who achieve adequate blood pressure control with antihypertensives, patients with resistant hypertension have a worse prognosis and consequently a higher risk of myocardial infarction, stroke and end-stage renal disease, with two to six times higher mortality (5,6).

The cause of uncontrolled hypertension is usually identified in secondary hypertension), with a prevalence of up to 30% among patients with resistant hypertension (7,8). In addition to secondary hypertension, it is important to rule out pseudoresistant hypertension, including that caused by non-adherence to treatment (4). In this regard, large observational studies have found that within one year, approximately 50% of patients stop taking antihypertensive medications for various reasons, such as inadequacy, adverse drug reactions, and socioeconomic variables (9).

Uncontrolled hypertension is significantly associated with increased sympathetic activity, which can be caused by afferent signals originating from the kidneys and the influence of sympathetic tone by stimulating hypothalamic centers (10). Chronic activation of renal sympathetic nerves is key in the pathogenesis of  hypertension through various mechanisms (reabsorption of salt and water in renal tubules, reduction of renal perfusion and consequently glomerular filtration rate, activation of the RAAS cascade) (9). Consequently, renal denervation (RDN) has emerged as a therapeutic option in conditions of overactive central sympathetic nervous system (10).

This chapter explores the role of SGLT2i in the treatment of hypertension, with a focus on their mechanisms of action, recent clinical evidence, and future implications. The introduction of this drug class may represent a paradigm shift in the management of UAH, offering new opportunities for more effective and individualized therapeutic strategies.

 KEYWORDS / KLJUČNE REČI:

uncontrolled hypertension, chronic activation of renal sympathetic nerves, renal denervation

REFERENCES / LITERATURA:

• Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023;25(8):737-747. doi:10.1111/ jch.14701
• Makukule A, Modjadji P, Thovhogi N, Mokgalaboni K, Kengne AP. Uncontrolled Hypertension, Treatment, and Predictors among Hypertensive Out-Patients Attending Primary Health Facilities in Johannesburg, South Africa. Healthcare (Basel). 2023;11(20):2783. doi:10.3390/healthcare 11202783
• Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431. doi:10.1161/ HYPERTENSION AHA.118.12191
• McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/ eurheartj/ehae178
• Dybiec J, Krzemińska J, Radzioch E, et al. Advances in the Pathogenesis and Treatment of Resistant Hypertension. Int J Mol Sci. 2023;24(16):12911. doi:10.3390/ijms241612911
• Shalaeva EV, Messerli FH. What is resistant arterial hypertension?. Blood Press. 2023;32(1):2185457. doi:10.1080/08037051.2023.21854577. Charles L, Triscott J, Dobbs B. Secondary Hypertension: Discovering the Underlying Cause. Am Fam Physician. 2017;96(7):453-461.
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-1642. doi:10.1161/CIRCULATIONAHA.-111.068064
• Goyal A, Jain H, Verma A, et al. The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives. Curr Probl Cardiol. 2024;49(2):102196. doi:10.1016/j.cpcardiol.2023.102196
• Fontes MAP, Marzano LAS, Silva CC, Silva ACS. Renal sympathetic denervation for resistant hypertension: where do we stand after more than a decade. J Bras Nefrol. 2020;42(1):67-76. doi:10.1590/2175-8239-JBN-2018-0213
• Pisano A, Iannone LF, Leo A, Russo E, Coppolino G, Bolignano D. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021;11(11):CD011499. Published 2021 Nov 22. doi:10.1002/14651858.CD011499.pub3
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi:10.1056/NEJMoa1402670
• Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multi-centre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957-1965. doi:10.1016/ S0140-6736(14)61942-5
• Böhm M, Mahfoud F, Townsend RR, et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial [published correction appears in Eur Heart J. 2019 Jul 14;40(27):2205. doi: 10.1093/eurheartj/ehz184]. Eur Heart J. 2019;40(9):743-751. doi:10.1093/eurheartj/ehy871
• Rey-García J, Townsend RR. Renal Denervation: A Review [published correction appears in Am J Kidney Dis. 2023 Jan;81(1):125. doi: 10.1053/j.ajkd.2022.10.003]. Am J Kidney Dis. 2022;80(4):527-535. doi:10.1053/j.ajkd.2022.03.015